Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.
作者信息
Huang Yijun, Wolf Siglinde, Koes David, Popowicz Grzegorz M, Camacho Carlos J, Holak Tad A, Dömling Alexander
机构信息
Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.
出版信息
ChemMedChem. 2012 Jan 2;7(1):49-52. doi: 10.1002/cmdc.201100428. Epub 2011 Sep 27.
Abstract
摘要
相似文献
1
Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.针对强效p53-Mdm2拮抗剂的全面氟扫描。
ChemMedChem. 2012 Jan 2;7(1):49-52. doi: 10.1002/cmdc.201100428. Epub 2011 Sep 27.
2
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.通过计算化学和多组分反应化学稳健生成用于蛋白质-蛋白质相互作用的先导化合物：p53/Hdm2拮抗剂
Angew Chem Int Ed Engl. 2010 Jul 19;49(31):5352-6. doi: 10.1002/anie.201001343.
3
Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.DS-5272作为一种有前景的候选药物的发现：一种强效且口服有效的p53-MDM2相互作用抑制剂。
Bioorg Med Chem. 2015 May 15;23(10):2360-7. doi: 10.1016/j.bmc.2015.03.069. Epub 2015 Mar 31.
4
Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction.寡苯甲酰胺类 p53-hDM2 蛋白-蛋白相互作用的模拟抑制剂。
Chem Commun (Camb). 2009 Sep 14(34):5091-3. doi: 10.1039/b908207g. Epub 2009 Jun 24.
5
Miniature protein inhibitors of the p53-hDM2 interaction.p53-hDM2相互作用的微型蛋白抑制剂
Chembiochem. 2006 Jan;7(1):29-31. doi: 10.1002/cbic.200500324.
6
Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.发现、合成和生物评价具有口服活性的吡咯烷酮衍生物作为新型 p53-MDM2 蛋白-蛋白相互作用抑制剂。
J Med Chem. 2012 Nov 26;55(22):9630-42. doi: 10.1021/jm300969t. Epub 2012 Oct 19.
7
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.发现 AM-7209，一种强效和选择性的 4-氨基苯甲酸抑制剂，可抑制 MDM2-p53 相互作用。
J Med Chem. 2014 Dec 26;57(24):10499-511. doi: 10.1021/jm501550p. Epub 2014 Dec 4.
8
Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.基于亲和力的 MDM2/MDMX-p53 相互作用抑制剂的化学筛选阵列：新型肽类抑制剂的鉴定。
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3802-5. doi: 10.1016/j.bmcl.2013.04.094. Epub 2013 May 15.
9
The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.中央缬氨酸概念为 p53-MDM2 相互作用的非肽类抑制剂提供了一个新的类别。
Bioorg Med Chem Lett. 2012 May 15;22(10):3498-502. doi: 10.1016/j.bmcl.2012.03.083. Epub 2012 Mar 30.
10
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.发现二氢异喹啉酮衍生物作为p53-MDM2相互作用的新型抑制剂，具有独特的结合模式。
Bioorg Med Chem Lett. 2015 Sep 1;25(17):3621-5. doi: 10.1016/j.bmcl.2015.06.058. Epub 2015 Jun 23.
引用本文的文献
1
Structure and Reactivity of Glycosyl Isocyanides.糖基异腈的结构与反应活性
European J Org Chem. 2019 Jan 10;2019(1):50-55. doi: 10.1002/ejoc.201801588. Epub 2018 Nov 22.
2
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.基于 Ugi 反应衍生配体的 MDM2 降解剂的开发：经验与发现。
Eur J Med Chem. 2021 Jul 5;219:113425. doi: 10.1016/j.ejmech.2021.113425. Epub 2021 Apr 4.
3
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.用于癌症治疗的小分子MDM2/X抑制剂和PROTAC降解剂：进展与展望
Acta Pharm Sin B. 2020 Jul;10(7):1253-1278. doi: 10.1016/j.apsb.2020.01.003. Epub 2020 Jan 14.
4
Controlling the stereochemistry in 2-oxo-aldehyde-derived Ugi adducts through the cinchona alkaloid-promoted electrophilic fluorination.通过金鸡纳生物碱促进的亲电氟化反应控制2-氧代醛衍生的乌吉加合物中的立体化学。
Beilstein J Org Chem. 2020 Aug 11;16:1963-1973. doi: 10.3762/bjoc.16.163. eCollection 2020.
5
Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions.竞争 NMR 检测蛋白-蛋白相互作用的命中/先导抑制剂。
Molecules. 2020 Jul 1;25(13):3017. doi: 10.3390/molecules25133017.
6
Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.近期的 p53-MDM2 蛋白-蛋白相互作用小分子抑制剂。
Molecules. 2020 Mar 7;25(5):1211. doi: 10.3390/molecules25051211.
7
Artificial Macrocycles.人工大环化合物
Synlett. 2018 Jun;29(9):1136-1151. doi: 10.1055/s-0036-1591975. Epub 2018 May 7.
8
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.基于吲哚和多组分反应的大环化合物作为p53-MDM2拮抗剂的设计
Beilstein J Org Chem. 2019 Feb 20;15:513-520. doi: 10.3762/bjoc.15.45. eCollection 2019.
9
A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53 osteosarcoma cells.一种基于氟吲哚的 MDM2 拮抗剂，能选择性抑制 p53 成骨肉瘤细胞的生长。
FEBS J. 2019 Apr;286(7):1360-1374. doi: 10.1111/febs.14774. Epub 2019 Feb 16.
10
Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.通过药效团和基于结构的虚拟筛选鉴定Mdm2-p53相互作用的新型抑制剂。
Drug Des Devel Ther. 2018 Nov 2;12:3741-3752. doi: 10.2147/DDDT.S182444. eCollection 2018.
本文引用的文献
1
Ligand Entropy in Gas-Phase, Upon Solvation and Protein Complexation. Fast Estimation with Quasi-Newton Hessian.气相、溶剂化及蛋白质络合过程中的配体熵。基于拟牛顿海森矩阵的快速估算
J Chem Theory Comput. 2010 Jul 13;6(7):2140-52. doi: 10.1021/ct100095p.
2
The p53-MDM2/MDMX axis - A chemotype perspective.p53-MDM2/MDMX轴——从化学型角度看
Medchemcomm. 2011;2:246-260. doi: 10.1039/C0MD00248H.
3
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists.实现小分子蛋白-蛋白拮抗剂的大规模设计、合成和验证。
PLoS One. 2012;7(3):e32839. doi: 10.1371/journal.pone.0032839. Epub 2012 Mar 12.
4
Methyl-monofluorination of ibuprofen selectively increases its inhibitory activity toward cyclooxygenase-1 leading to enhanced analgesic activity and reduced gastric damage in vivo.布洛芬的单甲基氟化选择性地增加了其对环氧化酶-1 的抑制活性，导致体内镇痛活性增强和胃损伤减少。
Bioorg Med Chem Lett. 2011 Jun 15;21(12):3578-82. doi: 10.1016/j.bmcl.2011.04.114. Epub 2011 May 3.
5
Aromatic rings in chemical and biological recognition: energetics and structures.化学和生物识别中的芳环：能量学和结构。
Angew Chem Int Ed Engl. 2011 May 16;50(21):4808-42. doi: 10.1002/anie.201007560. Epub 2011 Apr 28.
6
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.基于结构的 Mdm2/Mdmx-p53 抑制剂的设计变得越来越重要。
Angew Chem Int Ed Engl. 2011 Mar 14;50(12):2680-8. doi: 10.1002/anie.201003863. Epub 2011 Feb 21.
7
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.基于咪唑并[1,2-a]吡嗪核心的 Aurora 激酶抑制剂：氟和氘的引入可改善口服吸收和暴露。
J Med Chem. 2011 Jan 13;54(1):201-10. doi: 10.1021/jm1010995. Epub 2010 Dec 3.
8
Translating p53 into the clinic.将 p53 转化为临床应用。
Nat Rev Clin Oncol. 2011 Jan;8(1):25-37. doi: 10.1038/nrclinonc.2010.174. Epub 2010 Oct 26.
9
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.通过计算化学和多组分反应化学稳健生成用于蛋白质-蛋白质相互作用的先导化合物：p53/Hdm2拮抗剂
Angew Chem Int Ed Engl. 2010 Jul 19;49(31):5352-6. doi: 10.1002/anie.201001343.
10
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.1,4-噻吩并二氮杂*-2,5-二酮通过 MCR（I）合成：虚拟空间与 p53-Mdm2 活性。
Chem Biol Drug Des. 2010 Aug;76(2):116-29. doi: 10.1111/j.1747-0285.2010.00989.x. Epub 2010 May 18.
Zotero 插件